Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274051 | 0.90 | CES2 (0.50) | GAACES2CES1SRCKCNN4 | |
| SCHEMBL4245530 | 0.90 | GAA (0.53) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL11216011 | 0.82 | CES2 (0.44) | GAACES2CES1SRCKCNN4 | |
| SCHEMBL8209123 | 0.82 | CES2 (0.44) | GAACES2CES1SRCCNR2 | |
| SCHEMBL10624395 | 0.78 | SRC (0.46) | GAASRC | |
| SCHEMBL2628067 | 0.78 | GAA (0.50) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL29557378 | 0.78 | GAA (0.50) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL15430213 | 0.78 | GAA (0.50) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL6774538 | 0.78 | CES2 (0.61) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL27967493 | 0.78 | GAA (0.50) | GAACES2CES1KCNN4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| US-4329454-A | Cephalosporin compounds | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | GAA 1186/4885CES2 551/4885CES1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.